-
Mashup Score: 3Effectiveness of a bivalent mRNA vaccine booster dose to prevent severe COVID-19 outcomes: a retrospective cohort study - 1 year(s) ago
Participants who received a bivalent mRNA booster vaccine dose had lower rates of hospitalisation due to COVID-19 than participants who did not receive a bivalent booster vaccination, for up to 120 days after vaccination. These findings highlight the importance of bivalent mRNA booster vaccination in populations at high risk of severe COVID-19. Further studies with longer observation times are…
Source: The Lancet Infectious DiseasesCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 273Effectiveness of a bivalent mRNA vaccine booster dose to prevent severe COVID-19 outcomes: a retrospective cohort study - 1 year(s) ago
Participants who received a bivalent mRNA booster vaccine dose had lower rates of hospitalisation due to COVID-19 than participants who did not receive a bivalent booster vaccination, for up to 120 days after vaccination. These findings highlight the importance of bivalent mRNA booster vaccination in populations at high risk of severe COVID-19. Further studies with longer observation times are…
Source: The Lancet Infectious DiseasesCategories: Expert Picks, Latest HeadlinesTweet-
A 72% reduction of Covid hospitalizations with the bivalent (BA.5) booster vs not boosted in people age 65+ https://t.co/5Bw8YvZwvm @TheLancetInfDis @ClalitHealth @ClalitResearch @ArbelRonen and colleagues https://t.co/9eo6ES4up3
-
-
Mashup Score: 1
Repeated vaccination increases SARS-CoV-2-specific antibodies in KTRs, without further enhancement by use of a higher dose, a heterologous vaccine, or 2 weeks discontinuation of mycophenolate mofetil or mycophenolic acid. To achieve a stronger response, possibly required to neutralise new virus variants, repeated booster vaccination is needed.
Source: The Lancet Infectious DiseasesCategories: Infectious Disease, Latest HeadlinesTweet-
Practical! Kidney transplant recipients with poor response to their mRNA vaccine series were randomized to 1) a booster (and subset randomized to have their mycophenolate held x2 weeks) 2) double dose booster 3) Ad26.COV2-S booster (heterologous) 1/ https://t.co/TpnHVcoJmD
-
-
Mashup Score: 0
This systematic review, commissioned and funded by WHO, aimed to update a review of infection prevention and control (IPC) interventions at a national level to inform a review of their IPC Core Components guidelines (PROSPERO CRD42021297376). CENTRAL, CINAHL, Embase, MEDLINE, and WHO IRIS were searched for studies meeting Cochrane’s Effective Practice and Organisation of Care (EPOC) design…
Source: The Lancet Infectious DiseasesCategories: Infectious Disease, Latest HeadlinesTweet-
New review: Effectiveness of national and subnational interventions for prevention and control of health-care-associated infections in acute hospitals in high-income and upper-middle-income counties: a systematic review update https://t.co/DADLb2Hekx
-
-
Mashup Score: 3
LFDs remained able to detect most SARS-CoV-2 infections throughout vaccine roll-out and across different viral variants. LFDs can potentially detect most infections that transmit to others and reduce the risk of transmission. However, performance is lower in asymptomatic individuals than in symptomatic individuals.
Source: The Lancet Infectious DiseasesCategories: Infectious Disease, Latest HeadlinesTweet-
New research: Performance of antigen lateral flow devices in the UK during the alpha, delta, and omicron waves of the SARS-CoV-2 pandemic: a diagnostic and observational study https://t.co/GnVIS0ygSg
-
-
Mashup Score: 0
Rapid antigen test devices (also known as lateral flow devices; LFDs) have emerged as an important tool in the early detection of SARS-CoV-2.1 In The Lancet Infectious Diseases, David Eyre and colleagues describe the clinical performance of three different LFDs during the COVID-19 pandemic, assessed against successive waves of SARS-CoV-2 variants (alpha [B.1.1.7] and pre-alpha [B.1.177]; delta…
Source: The Lancet Infectious DiseasesCategories: Infectious Disease, Latest HeadlinesTweet-
And the linked comment: The performance of rapid antigen tests against SARS-CoV-2 variants https://t.co/RYVFdDVLwl
-
-
Mashup Score: 0Economic evaluations of interventions to prevent and control health-care-associated infections: a systematic review - 1 year(s) ago
Almost 9 million health-care-associated infections have been estimated to occur each year in European hospitals and long-term care facilities, and these lead to an increase in morbidity, mortality, bed occupancy, and duration of hospital stay. The aim of this systematic review was to review the cost-effectiveness of interventions to limit the spread of health-care-associated infections), framed…
Source: The Lancet Infectious DiseasesCategories: Infectious Disease, Latest HeadlinesTweet-
New review: Economic evaluations of interventions to prevent and control health-care-associated infections: a systematic review https://t.co/pWWPaAXXCX
-
-
Mashup Score: 0New boosters are here! Who should receive them and when? - 1 year(s) ago
The FDA has authorised bivalent booster vaccines containing mRNA for the ancestral SARS-CoV-2 variant as well as B.1.1.529.4 (BA.4) and B.1.1.529.5 (BA.5), the latter being the most prevalent omicron subvariant circulating now.
Source: The Lancet Infectious DiseasesCategories: Expert Picks, Latest HeadlinesTweet-
Aligns with the recommendations @ShiraDoronMD and I provided in this @TheLancetInfDis article (peer reviewed) & most countries' guidance. Who is still at risk of severe disease? Boost https://t.co/YJzM7VNd1G
-
-
Mashup Score: 1Promoting diversity and equity in publishing - 1 year(s) ago
As the chief executive officer of Google and its parent company Alphabet, Sundar Pichai said, “A diverse mix of voices leads to better discussions, decisions, and outcomes for everyone”. Diversity, equity, and inclusion (DEI) are important at every stage of the publishing process, from content to authors and editorial teams. Publishing is not a level playing field and not everyone has the same…
Source: The Lancet Infectious DiseasesCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
RT @TheLancetInfDis: New editorial: Promoting diversity and equity in publishing https://t.co/lF5ReeoERM
-
-
Mashup Score: 3Balancing tuberculosis therapy and substance use - 1 year(s) ago
Tuberculosis (TB) is a major cause of illness and death globally, the annual WHO Global TB Report stated that 1·6 million people died from TB in 2022. In South Africa, TB remains the leading cause of death. The focal points of this epidemic are institutions like residential hospital DP Marais, in Cape Town, South Africa, which is the principle setting of Anna Versfeld’s recent book Making…
Source: The Lancet Infectious DiseasesCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @TheLancetInfDis: New media watch: Balancing tuberculosis therapy and substance use https://t.co/RslaVUNzew
-
Retrospective population-based cohort study of 570K people age 65+ from Israel: those who received an updated bivalent #COVID19 #boostershot had 72% reduction in risk of hospitalization. If you haven’t had one yet, #GetBoosted. #MedTwitter https://t.co/iohu3RB28L https://t.co/eI9vQKrwO9